Circadian rhythm drives the release of important immune cells

Research reveals it's driven by Earth’s 24-hour day/night cycle

3:36 PM

Author | Kelly Malcom

woman laying on floating cell maroon
Jacob Dwyer, Michigan Medicine

The sites where our bodies come into contact with the outside world—via skin, the surface of the eye, inside the mouth, the lining of the intestine and the urinary tract, for example—are known as barrier tissues. 

Helping to defend those tissues are innate lymphoid cells, or ILCs, which when faced with a threat, stimulate proteins called cytokines that further activate the immune system and control intestinal microbiome. 

These cells naturally diminish with aging or can be depleted by certain medical conditions. 

ILCs are made inside bone marrow and circulate in the blood. But how are they activated to mobilize and travel to their target sites to replenish the depleted pool of tissue ILCs? 

A Michigan Medicine study reveals that this migration is ruled by circadian rhythms and are one of the many biological functions dictated by the Earth’s 24-hour day/night cycle. 

To determine this, the team, led by Chang H. Kim, Ph.D., professor of Pathology and the Kenneth and Judy Betz Research Professor, Mary H. Weiser Food Allergy Center, looked at how the process plays out in mice, who are active at night and sleep during the day.  

For both mice and humans, a stress hormone called cortisol peaks upon awakening, while a decrease in cortisol and an increase in melatonin and adenosine bring on feelings of sleepiness. 

The investigators discovered that ILCPs (progenitor cells that go on to become ILCs), heavily express so-called clock genes that lead to them being active at different times of the day.  

Specifically, they found that cortisol increases activation of a chemoattractant receptor called CXCR4 on ILCPs to keep them inside the bone marrow. 

At the time of rest, the cytokine interleukin-18 and a receptor called RORα activate the receptor S1PR1 on ILCPs, triggering them to be released from the bone marrow into the blood. 

“Building cells takes time. Instead of constantly releasing cells as they are made, we think that to maximize efficiency, the body synchronizes to a rhythm where you build up ILCPs for 12 hours while animals are active and then release them while sleeping,” said Kim.  

This process is repeated daily and is necessary to maintain adequate levels of barrier tissue ILCs in the gut.  

“What this suggests is if you mess up your circadian rhythm, you decrease ILCs in the tissue, making you more vulnerable to infection and an imbalance in your microbiome,” Kim said. 

Understanding how ILCs are mobilized on a circadian rhythm is an important concept that could be applied to other types of stem cells and eventually applied for certain cell therapies, he notes. 

Additional authors include Qingyang Liu, Shams Tabrez, and Patrick Niekamp 

This work was made possible in part through use of the U-M Advanced Genomics Core.

Paper cited: “Circadian-clock-controlled endocrine and cytokine signals regulate multipotential innate lymphoid cell progenitors in the bone marrow,” Cell Reports. DOI: https://doi.org/10.1016/j.celrep.2024.114200. 

 

Sign up for Health Lab newsletters today. Get medical tips from top experts and learn about new scientific discoveries every week by subscribing to Health Lab’s two newsletters, Health & Wellness and Research & Innovation. 

Sign up for the Health Lab Podcast: Add us on Spotify, Apple Podcasts or wherever you get you listen to your favorite shows. 


More Articles About: Allergy and Immunology Pathology All Research Topics Wellness & Prevention Basic Science and Laboratory Research
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories blue cell and red cell merging on dark blue screen
Health Lab
New cellular therapy trials for brain tumors
Michigan Medicine experts discuss CAR T therapy, its use in other clinical trials at U-M and the new Phase I trials that started in March 2025.
xray brain images on repeat and person pointing with pointer
Health Lab
Re-purposed FDA-approved drug could help treat high-grade glioma
Avapritinib, an FDA-approved drug used to treat other types of cancer, also decreases aggressive gliomas in animal models and in an initial cohort of patients with high-grade glioma.
2025 blocks with stethoscope
Health Lab
Top 10 things to know about your health costs right now
From Medicare prescription costs and medical debt rules to actions that the Supreme Court, Congress and President Trump could take, a guide to health policies that affect many people.
red rash on elbow
Health Lab
Study doubles number of genetic signals for psoriasis
A large genome wide association study (GWAS) of psoriasis identifies new susceptibility variants that underlie this common, yet enigmatic, skin disease.
boy smiling in red shirt sitting
Health Lab
A heart on Valentines Day: young man with rare disease gets second transplant
A young man from Michigan who was born with the rare disease Barth Syndrome received a new heart over two decades after having a heart transplant as an infant.
drawing of scientists and doctors up close to insides of stomach
Health Lab
How a phone call led Michigan Medicine to become a leader in treating severe ulcerative colitis
Michigan Medicine becomes leader in treating severe ulcerative colitis with JAK inhibitors.